About Kidney Cancer Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.
Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.
Technavio's analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.
Request For Sample Report @ https://www.wiseguyreports.com/sample-request/69824-global-kidney-cancer-drugs-market-2015-2019
Covered in this Report The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.
The three regions covered in the report are as follows: • Americas: US, Canada, Mexico, and Brazil
• EMEA: UK, Germany, Italy, France, and Spain and Middle Eastern and African countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
• APAC: Japan, China, Australia, Singapore, South Korea, and India.
Technavio's report, Global Kidney Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions • Americas
• APAC
• EMEA
Key Vendors • Bayer
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Pfizer
Other Prominent Vendors • Abbott Laboratories
• Active Biotech
• Amgen
• Argos Therapeutics
• ArQule
• AVEO Pharmaceuticals
• Bionomics
• Bristol-Myers Squibb
• Cerulean Pharma
• Exelixis
• Genentech
• immatics biotechnologies
• Immunicum
• Ono Pharmaceutical
• Onyx Therapeutics
• Oxford BioMedica
• Prometheus Laboratories
• Seattle Genetics
• Taiwan Liposome
• TRACON Pharmaceuticals
• Wilex
Market Driver • Increase in Patient Population
• For a full, detailed list, view our report
• For a full, detailed list, view our report
Market Challenge • High Cost of Drugs
• For a full, detailed list, view our report
Market Trend • Strategic Alliances
• For a full, detailed list, view our report
Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Complete Report Details @ https://www.wiseguyreports.com/reports/69824-global-kidney-cancer-drugs-market-2015-2019
Table of Contents
- Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1.1 Nexavar
05.1.2 Avastin
05.1.3 Votrient
05.1.4 Afinitor/Votubia
05.1.5 Proleukin
05.1.6 Inlyta
05.1.7 Sutent
05.1.8 Torisel
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.1.1 Types of Kidney Cancer
07.1.2 Benign Kidney Tumors
07.2 Risk Factors
07.2.1 Lifestyle and Job-related Risk Factors
07.2.2 Genetic and Hereditary Risk Factors
07.2.3 Other Risk Factors
07.3 Etiology and Pathogenesis
07.3.1 Inherited Gene Mutations
07.3.2 Acquired Gene Mutations
07.4 Signs and Symptoms
07.5 Diagnosis
07.5.1 Medical History and Physical Exam
07.5.2 Lab Tests
07.5.3 Imaging Tests
07.5.4 Biopsy
07.6 Staging
07.6.1 TNM Staging System
07.7 Management
07.7.1 Surgery
07.7.2 Ablation and Other Local Therapies
07.7.3 Radiation Therapy
07.7.4 Targeted Therapy
07.7.5 Biologic Therapy (Immunotherapy)
07.7.6 Chemotherapy
07.8 Epidemiology
07.9 Economic Burden
08. Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 AGS-003
08.1.2 Rencarex
08.1.3 Cometriq
08.1.4 IMA901
08.1.5 AV-951
08.1.6 TroVax
08.1.7 MPDL3280A
08.1.8 Opdivo
08.1.9 Naptumomab Estafenatox
08.1.10 Carfilzomib
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Market Segmentation by Molecule Type
10.1 Small Molecules
10.2 Biologics
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and Their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and Their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Bayer
19.2.2 F. Hoffmann-La Roche
19.2.3 GlaxoSmithKline
19.2.4 Novartis
19.2.5 Pfizer
19.3 Other and Future Prominent Vendors
20. Global Kidney Cancer Drugs Market: Key Takeaways
21. Key Vendor Analysis
21.1 Bayer
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2014
21.1.4 Business Segmentation by Revenue 2013 and 2014
21.1.5 Geographical Segmentation by Revenue 2014
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2014
21.3.4 Business Segmentation by Revenue 2013 and 2014
21.3.5 Geographical Segmentation by Revenue 2014
21.3.6 Business Strategy
21.3.7 Recent Developments
21.3.8 SWOT Analysis
21.4 Novartis
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Pfizer
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2014
21.5.4 Business Segmentation by Revenue 2013 and 2014
21.5.5 Geographical Segmentation by Revenue 2014
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis
22. Other Reports in This Series
Continued…….
CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment